SCHEMBL4039283

SCHEMBL4039283

N#Cc1nn(-c2c(Cl)cc(C(F)(F)F)cc2Cl)c(NCc2ccncc2)c1SC(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 12/20 0.41
GABRD O14764 12/20 0.41
GABRA1 P14867 12/20 0.41
GABRB1 P18505 12/20 0.41
GABRG2 P18507 12/20 0.41
GABRB3 P28472 12/20 0.41
GABRA5 P31644 12/20 0.41
GABRA3 P34903 12/20 0.41
GABRA2 P47869 12/20 0.41
GABRB2 P47870 12/20 0.41
GABRA4 P48169 12/20 0.41
GABRE P78334 12/20 0.41
GABRA6 Q16445 12/20 0.41
GABRG1 Q8N1C3 12/20 0.41
GABRG3 Q99928 12/20 0.41
GABRQ Q9UN88 12/20 0.41
LMNA P02545 3/20 0.41
NR1I2 O75469 1/20 0.41
CYP3A4 P08684 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14209955 0.91 GABRP (0.45) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL4854540 0.90 GABRP (0.41) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL5217113 0.85 GABRB3 (0.40) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL14208660 0.84 GABRP (0.39) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL6055762 0.82 GABRB3 (0.44) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL7669983 0.82 GABRP (0.36) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL3370802 0.81 GABRB3 (0.42) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL712966 0.81 GABRB3 (0.47) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2001797 0.80 GABRB3 (0.39) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL6623244 0.79 GABRB3 (0.43) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9609871-B2 Combination product for controlling parasites on animals BAYER INTELLECTUAL PROPERTY GMBH (DE) 2017-04-04 US disclosed
US-9609871-B2 Combination product for controlling parasites on animals BAYER INTELLECTUAL PROPERTY GMBH (DE) 2017-04-04 US disclosed
US-20160007611-A1 Combination product for controlling parasites on animals ELANCO ANIMAL HEALTH GMBH (DE) 2016-01-14 US disclosed
US-20160007611-A1 Combination product for controlling parasites on animals ELANCO ANIMAL HEALTH GMBH (DE) 2016-01-14 US disclosed
EP-2104428-B1 COMBINATION PRODUCT FOR CONTROLLING PARASITES ON ANIMALS BAYER IP GMBH (DE) 2015-10-14 EP disclosed
US-9137995-B2 Combination product for controlling parasites on animals BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-09-22 US disclosed
US-9137995-B2 Combination product for controlling parasites on animals BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-09-22 US disclosed
US-20130045996-A1 COMBINATION PRODUCT FOR CONTROLLING PARASITES ON ANIMALS BAYER ANIMAL HEALTH GMBH (DE) 2013-02-21 US disclosed
US-20130045996-A1 COMBINATION PRODUCT FOR CONTROLLING PARASITES ON ANIMALS BAYER ANIMAL HEALTH GMBH (DE) 2013-02-21 US disclosed
US-20130012562-A1 Composition for Controlling Parasites on Animals BAYER ANIMAL HEALTH GMBH (DE) 2013-01-10 US disclosed
US-20100016398-A1 COMBINATION PRODUCT FOR CONTROLLING PARASITES ON ANIMALS BAYER ANIMAL HEALTH GMBH (DE) 2010-01-21 US disclosed
US-20100016398-A1 COMBINATION PRODUCT FOR CONTROLLING PARASITES ON ANIMALS BAYER ANIMAL HEALTH GMBH (DE) 2010-01-21 US disclosed
US-20090312387-A1 COMPOSITION FOR CONTROLLING PARASITES ON ANIMALS BAYER ANIMAL HEALTH GMBH (DE) 2009-12-17 US disclosed
US-20090312387-A1 COMPOSITION FOR CONTROLLING PARASITES ON ANIMALS BAYER ANIMAL HEALTH GMBH (DE) 2009-12-17 US disclosed
EP-0976737-B1 PYRAZOLE DERIVATIVES, PROCESS FOR PREPARING THE SAME, INTERMEDIATES, AND PEST CONTROL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT NIHON NOHYAKU CO LTD (JP) 2009-06-10 EP disclosed
WO-2008080542-A2 COMBINATION PRODUCT FOR CONTROLLING PARASITES ON ANIMALS BAYER ANIMAL HEALTH GMBH (DE) 2008-07-10 WO disclosed
WO-2008080541-A1 AGENTS FOR CONTROLLING PARASITES ON ANIMALS BAYER ANIMAL HEALTH GMBH (DE) 2008-07-10 WO disclosed
US-7371768-B2 Pyrazol derivatives, pest control agent comprising the same as active ingredient, and process for producing the same NIHON NOHYAKU CO., LTD. (JP) 2008-05-13 US disclosed
US-6335357-B1 1-ARYL-3-CYANO-5-(HET)ARYLALKYLAMINOPYRAZOLE DERIVATIVES; INSECTICIDES FOR AGRICULTURE AND HORTICULTURE MITSUBISHI CHEMICAL CORPORATION (JP) 2002-01-01 US disclosed
EP-0976737-A1 PYRAZOLE DERIVATIVES, PROCESS FOR PREPARING THE SAME, INTERMEDIATES, AND PEST CONTROL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT MITSUBISHI CHEMICAL CORPORATION (JP) 2000-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160007611-A1 Combination product for controlling parasites on animals CYCS, CYP3A43, CDIPT GABRP 68/4885GABRD 346/4885GABRA1 385/4885
US-20100016398-A1 COMBINATION PRODUCT FOR CONTROLLING PARASITES ON ANIMALS CYCS, CYP3A43, CDIPT GABRP 68/4885GABRD 346/4885GABRA1 385/4885
US-20130045996-A1 COMBINATION PRODUCT FOR CONTROLLING PARASITES ON ANIMALS CYCS, CYP3A43, CDIPT GABRP 68/4885GABRD 346/4885GABRA1 385/4885
US-20090312387-A1 COMPOSITION FOR CONTROLLING PARASITES ON ANIMALS CYCS, PTMS, PLCB3 GABRP 687/4885GABRD 3073/4885GABRA1 2122/4885
US-20130012562-A1 Composition for Controlling Parasites on Animals CYCS, PTMS, PLCB3 GABRP 687/4885GABRD 3073/4885GABRA1 2122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.